The cost of developing new drugs continues to climb, with estimates often exceeding $2 billion per therapy, even as failure rates in clinical trials remain high. At the same time, chronic diseases such as cancer and diabetes account for hundreds of billions in annual U.S. healthcare spending, exposing a persistent inefficiency in how treatments are discovered and brought to market.
For pharmaceutical companies and investors, the implications are structural. Long development timelines and late-stage failures tie up capital and slow the pace of innovation. The ability to identify viable drug candidates earlier in the pipeline has become a key differentiator, particularly as competition intensifies across the biotechnology sector.
Researchers working at the intersection of computational science and medicinal chemistry are beginning to address that gap. Victor Nwankwo, a pharmaceutical sciences researcher focused on drug discovery, is part of a broader shift toward data-driven approaches that aim to reduce risk and improve efficiency in early-stage development. His work focuses on designing targeted therapies that address drug resistance and treatment failure, two of the most persistent and costly challenges in modern medicine.
“The identification and optimization of drug candidates is being revolutionized by current technologies like artificial intelligence, machine learning, and structure-based drug design, which drastically cut down on the time and expense involved with conventional trial-and-error methods in drug discovery and development,” Nwankwo said.
The shift toward computational modeling allows researchers to screen large numbers of potential compounds before laboratory testing begins, narrowing the field to the most promising candidates. That approach reduces the number of costly experiments and increases the likelihood that compounds entering preclinical and clinical stages will succeed. For biotech firms, the result is a more capital-efficient model with shorter development cycles.
At the same time, advances in targeted therapies are expanding what pharmaceutical companies can pursue. Technologies such as proteolysis-targeting chimeras, or PROTACs, are reshaping how certain diseases are treated by moving beyond traditional inhibition strategies.
“PROTAC technology is changing the way pharmaceutical companies approach therapeutic intervention, moving away from merely inhibiting undruggable proteins and toward actively eliminating them from the cell,” Nwankwo said.
By leveraging the body’s natural protein degradation systems, PROTAC-based therapies aim to remove disease-causing proteins entirely, rather than temporarily blocking their function. That distinction has implications for durability and resistance, two factors that have historically limited the effectiveness of many cancer treatments.
For the broader industry, these advances are also lowering barriers to entry. Smaller biotechnology companies are increasingly able to compete by using computational tools to generate high-value drug candidates without the same level of upfront investment required in traditional models. Larger pharmaceutical firms are expanding partnerships and acquisitions to access these emerging capabilities.
“These technologies enable smaller teams to produce high-value drug candidates, thereby reducing some of the conventional hurdles to entry for emerging biotech companies,” Nwankwo said.
The result is a more distributed and collaborative ecosystem, where academic research, startups, and established pharmaceutical companies play complementary roles. Universities continue to generate early-stage discoveries, while industry partners provide the capital, infrastructure, and regulatory expertise needed to bring therapies to market.
Looking ahead, the integration of computational methods with biological research is expected to accelerate further. As datasets expand and predictive models improve, drug discovery is likely to become more targeted, data-driven, and efficient.
For the U.S., maintaining leadership in biotechnology will depend on its ability to translate these advances into scalable therapies. Reducing the cost and time required to develop new drugs not only improves industry economics but also determines how quickly new treatments reach patients. In that context, the shift toward computationally driven drug discovery is less an incremental improvement and more a structural change in how the industry operates. If scaled, Nwankwo’s approach could influence how new therapies are developed across the industry, improving outcomes for millions of patients while reducing long-term healthcare costs.
